By Marie Rosenthal, MS
The FDA approved dolutegravir-rilpivirine (Juluca, ViiV Healthcare), the first complete treatment regimen containing only two drugs for the maintenance treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL).
Dolutegravir-rilpivirine (50-25 mg) is a fixed-dose, once-daily tablet containing two previously approved drugs to treat HIV-positive adults on a stable antiretroviral (ART) regimen for at least six months with no